GABA Therapeutics is developing GRX-917, an anxiety medication with comparable efficacy to benzodiazepines like Xanax, but with minimal to no side effects. It also increases brain neurosteroid biosynthesis, which could benefit a broad range of neuropsychiatric and neurological disorders.